Gerhard Koenig, Arkuda CEO

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the clin­ic

In the bustling biotech space, a cou­ple years can feel like an eter­ni­ty — but for an At­las Ven­ture-backed neu­rol­o­gy play­er with a nov­el spin on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.